Market Size of France In-Vitro Diagnostics Industry
Study Period | 2019 - 2029 |
Base Year For Estimation | 2023 |
Forecast Data Period | 2024 - 2029 |
Historical Data Period | 2019 - 2022 |
CAGR | 7.50 % |
Market Concentration | Low |
Major Players*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
France In-Vitro Diagnostics Market Analysis
France In-Vitro Diagnostic Market is expected to witness a CAGR of 7.5% over the forecast period.
The emergence of the COVID-19 pandemic had a significant impact on France in-vitro diagnostic market owing to the factors such as delayed diagnostic tests and the scarcity of laboratory reagents to perform tests. For instance, as per the article published in March 2022 in PubMed, based on data from the French administrative healthcare database (SNDS) on the entire French population (67 million people), screening, diagnostic and therapeutic activity was monitored and compared the post-pandemic situation every month, and a significant decline in all activities was observed during the first lockdown in France. However, COVID-19 diagnostic tests were widely carried out during the pandemic, which was one of the factors that significantly affected the market growth. The market is anticipated to witness growth in the coming years due to the rise in chronic diseases and the increase in demand for early diagnosis and point of care.
Certain factors that are also propelling the market growth are the rising incidence of chronic diseases, increasing awareness and acceptance of personalized medicine and companion diagnostics, and the increasing use of point-of-care (POC) diagnostics. The rising burden of chronic diseases such as infectious diseases, cardiovascular diseases, cancers, and others is the main factor driving the demand for the in-vitro diagnostics market over the forecast period. For instance, according to the IDF Atlas 10th edition published in 2021, about 3,942.9 thousand people were living with diabetes in France in 2021. In addition, as per the same source, this number is projected to reach 4,184.9 thousand by 2030 and 4,225.7 thousand by 2045. Furthermore, the increasing use of point-of-care diagnostics in the country as well as initiatives taken to increase awareness and testing for chronic diseases, is also contributing to the growth of the market. For instance, In March 2022, France launched a new colon-cancer testing system for people aged 50-74 years.
Thus, due to the rise in chronic diseases, and the increase in invitro diagnostics product launches, the France in-vitro diagnostics market is anticipated to witness growth in the market over the forecast period. However, the stringent regulations related to diagnostic equipment and devices are impeding the market growth over the forecast period.
France In-Vitro Diagnostics Industry Segmentation
As per the scope of this report, in vitro diagnostics involves medical devices and consumables that are utilized to perform in vitro tests on various biological samples. They are used for the diagnosis of various medical conditions, such as diabetes, cancer, and others. The France In-Vitro Diagnostics Market is Segmented by Test Type (Clinical Chemistry, Molecular Diagnostics, Immuno Diagnostics, and Other Techniques), Product (Instrument, Reagent, and Other Products), Usability (Disposable IVD Devices, Reusable IVD Devices), Application (Infectious Disease, Diabetes, Cancer/Oncology, Cardiology, and Other Applications) and End-users (Diagnostic Laboratories, Hospitals, and Clinics and Other End-users). The report offers the value (in USD million) for the above segments.
By Test Type | |
Clinical Chemistry | |
Molecular Diagnostics | |
Immuno Diagnostics | |
Other Techniques |
By Product | |
Instrument | |
Reagent | |
Other Product |
By Usability | |
Disposable IVD Devices | |
Reusable IVD Devices |
By Application | |
Infectious Disease | |
Diabetes | |
Cancer/Oncology | |
Cardiology | |
Other Applications |
By End-users | |
Diagnostic Laboratories | |
Hospitals and Clinics | |
Other End-users |
France In-Vitro Diagnostics Market Size Summary
The in-vitro diagnostics market in France is poised for significant growth, driven by the increasing prevalence of chronic and infectious diseases, alongside a rising demand for early diagnosis and point-of-care solutions. The market experienced initial challenges due to the COVID-19 pandemic, which caused delays in diagnostic tests and reagent shortages. However, the pandemic also spurred a surge in COVID-19 testing, contributing to market expansion. The growing incidence of chronic conditions such as diabetes, cardiovascular diseases, and cancers is a primary factor propelling market demand. Additionally, the market is benefiting from heightened awareness and acceptance of personalized medicine and companion diagnostics, as well as the expanding use of point-of-care diagnostics. Despite the positive growth trajectory, stringent regulations concerning diagnostic equipment and devices pose challenges to market expansion.
The infectious diseases segment is expected to see substantial growth, fueled by the rising prevalence of diseases like HIV/AIDS, tuberculosis, and hepatitis, as well as the ongoing demand for effective diagnostic solutions. The molecular diagnostics segment is also anticipated to grow significantly, driven by the increasing incidence of chronic diseases and the need for advanced diagnostic tests. The French in-vitro diagnostics market is characterized by a fragmented landscape with numerous local and international players, including Abbott Laboratories, F. Hoffmann-La Roche AG, QIAGEN N.V., and Siemens Healthineers AG. Recent product launches and strategic collaborations are expected to further enhance the availability and adoption of molecular diagnostics in the country. Overall, the market is set to expand, supported by technological advancements and a robust healthcare infrastructure.
France In-Vitro Diagnostics Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Rising Prevalence of Chronic Diseases
-
1.2.2 Increasing Awareness and Acceptance of Personalized Medicine and Companion Diagnostics
-
1.2.3 Increasing Use of Point-of-care (POC) Diagnostics
-
-
1.3 Market Restraints
-
1.3.1 Stringent Regulations
-
-
1.4 Porter Five Forces
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size by Value in USD million)
-
2.1 By Test Type
-
2.1.1 Clinical Chemistry
-
2.1.2 Molecular Diagnostics
-
2.1.3 Immuno Diagnostics
-
2.1.4 Other Techniques
-
-
2.2 By Product
-
2.2.1 Instrument
-
2.2.2 Reagent
-
2.2.3 Other Product
-
-
2.3 By Usability
-
2.3.1 Disposable IVD Devices
-
2.3.2 Reusable IVD Devices
-
-
2.4 By Application
-
2.4.1 Infectious Disease
-
2.4.2 Diabetes
-
2.4.3 Cancer/Oncology
-
2.4.4 Cardiology
-
2.4.5 Other Applications
-
-
2.5 By End-users
-
2.5.1 Diagnostic Laboratories
-
2.5.2 Hospitals and Clinics
-
2.5.3 Other End-users
-
-
France In-Vitro Diagnostics Market Size FAQs
What is the current France In-Vitro Diagnostics Market size?
The France In-Vitro Diagnostics Market is projected to register a CAGR of 7.5% during the forecast period (2024-2029)
Who are the key players in France In-Vitro Diagnostics Market?
Thermo Fischer Scientific Inc, QIAGEN N.V., Siemens Healthcare GmbH, F. Hoffmann-La Roche AG and Abbott Laboratories are the major companies operating in the France In-Vitro Diagnostics Market.